Orzeyful and Modafinil: What’s the Difference for People With Narcolepsy?

For people with narcolepsy, the FDA approval of Orzeyful in August 2026 introduced something genuinely new. Modafinil has been used for decades to help people with narcolepsy stay awake during the day. Orzeyful takes a different approach: it directly activates part of the orexin system, the brain signalling system that is severely disrupted in narcolepsy type 1.

Orzeyful and modafinil have different roles: modafinil is primarily a wake-promoting medication, while Orzeyful was developed around the orexin biology of narcolepsy type 1 and has demonstrated effects on wakefulness, daytime sleepiness and cataplexy.

What Is Narcolepsy?

Narcolepsy is a chronic neurological sleep disorder that makes it difficult for the brain to maintain stable periods of sleep and wakefulness.

The most recognisable symptom is excessive daytime sleepiness. This is more than simply feeling tired after a poor night’s sleep. A person with narcolepsy may struggle to remain awake during ordinary activities and may fall asleep unexpectedly.

Other symptoms can include:

• cataplexy, or sudden temporary loss of muscle tone
• disrupted nighttime sleep
• sleep paralysis
• vivid hallucinations when falling asleep or waking
• difficulty maintaining attention and alertness

Not everyone experiences all of these symptoms, and severity can vary considerably.

Narcolepsy is generally divided into type 1 and type 2.

What Are Narcolepsy Type 1 and Type 2?

Narcolepsy Type 1

Narcolepsy type 1, or NT1, is the form most closely associated with cataplexy and severe loss of orexin signalling.

Cataplexy is a sudden loss of muscle tone while a person remains conscious. Strong emotions such as laughter, excitement, anger or surprise can trigger it. An episode may involve drooping of the jaw or eyelids, weakness in the knees, slurred speech or, in more severe cases, collapse.

People with NT1 have usually lost most of the neurons in the hypothalamus that produce orexin, also called hypocretin. Orexin plays an important role in stabilising wakefulness and controlling transitions between sleep and wake states.

Narcolepsy Type 2

Narcolepsy type 2 also causes excessive daytime sleepiness, but cataplexy is absent.

NT2 is defined by the absence of cataplexy and is not characterised by the profound hypocretin deficiency that defines NT1.

The distinction is therefore more than a naming convention. It helps explain why Orzeyful is currently approved for NT1 rather than narcolepsy in general.

How Is Narcolepsy Diagnosed?

Symptoms alone are not usually enough to establish a diagnosis.

A sleep specialist may begin with a medical and sleep history, including how often daytime sleepiness occurs and whether cataplexy is present. People may also be asked to keep a sleep diary or wear an activity monitor.

Formal testing commonly includes an overnight polysomnogram, followed by a multiple sleep latency test the next day. The multiple sleep latency test measures how quickly someone falls asleep during several scheduled daytime naps and whether REM sleep appears unusually quickly.

In some cases, cerebrospinal fluid can also be tested for hypocretin. Very low hypocretin levels support a diagnosis of NT1.

Diagnosis matters because excessive daytime sleepiness can have many other causes, including insufficient sleep, sleep apnea and medications that cause drowsiness.

What Is the Main Difference Between Orzeyful and Modafinil?

Modafinil promotes wakefulness. Orzeyful directly activates a signalling pathway that is deficient in narcolepsy type 1.

Modafinil has long been used to help people with narcolepsy remain awake during the day, but it was not developed to replace the missing orexin signal.

Orzeyful, by contrast, is a selective orexin receptor 2 agonist. It stimulates a receptor that orexin would normally activate.

This places Orzeyful closer to the known biology of NT1, although it remains a symptomatic treatment rather than a cure.

The FDA described Orzeyful as the first approved treatment to directly restore orexin signalling in NT1.

What Is Modafinil and How Does It Work?

Modafinil is a prescription wake-promoting medication sold under the brand name Provigil and also available as a generic.

In the United States, it is approved to improve wakefulness in adults with excessive sleepiness associated with:

• narcolepsy
• obstructive sleep apnea
• shift work disorder

For narcolepsy, its main role is reducing excessive daytime sleepiness and helping people remain awake.

Modafinil’s exact wake-promoting mechanism is not known. In vitro, it binds to the dopamine transporter and inhibits dopamine reuptake; this activity has been associated with increased extracellular dopamine in some brain regions in animal studies.

Importantly, modafinil does not correct the orexin deficiency characteristic of NT1.

What Is Orzeyful and How Does It Work?

Orzeyful is the brand name for oveporexton, an oral selective orexin receptor 2, or OX2R, agonist developed by Takeda. Because NT1 involves severe loss of orexin signalling, oveporexton directly activates the OX2 receptor downstream of the missing signal.

In simple terms, the drug attempts to restore part of that signalling by directly stimulating the receptor.

That is why its mechanism is considered fundamentally different from traditional wake-promoting drugs.

Do Orzeyful and Modafinil Treat the Same Symptoms?

The drugs overlap in their effects on daytime sleepiness and wakefulness, but their approved indications, mechanisms and studied outcomes differ.

Feature	Modafinil	Orzeyful
Excessive daytime sleepiness	Approved use in narcolepsy	Improved in NT1 trials
Ability to remain awake	Improves wakefulness	Improved in NT1 trials
Cataplexy	Not primarily a cataplexy treatment	Reduced in phase 3 trials
Targets orexin signalling directly	No	Yes
FDA-approved for NT1 specifically	No, label is not restricted by narcolepsy subtype	Yes
FDA-approved for NT2	Label is not restricted by narcolepsy subtype	No

This is a comparison of approved uses, mechanisms and studied outcomes. It is not a head-to-head efficacy comparison.

How Modafinil Changed Narcolepsy Treatment, and How Orexin Changed What We Understood

Modafinil entered narcolepsy treatment before researchers fully understood the importance of orexin.

Early clinical use of modafinil began in Europe in the 1980s, and the medication later became established as a wake-promoting treatment for people with narcolepsy. Modafinil received its initial U.S. approval in 1998, the same year orexin/hypocretin was first described.

Within the next few years, researchers showed that disrupting orexin signalling could cause narcolepsy-like symptoms in animals and that people with narcolepsy and cataplexy frequently had a profound loss of orexin-producing neurons.

Medicine had therefore learned how to improve wakefulness pharmacologically before researchers fully understood one of the central biological abnormalities underlying NT1.

Orzeyful represents the next part of that story: a drug designed specifically around the orexin system itself.

What Did the Orzeyful Clinical Trials Find?

FDA approval was supported in part by two phase 3 studies called First Light and Radiant Light, later published in the New England Journal of Medicine.

Together, the studies enrolled 273 participants aged 16 to 70 with NT1 and compared twice-daily oveporexton with placebo for 12 weeks. The U.S. approval, however, is limited to adults.

Ability to Stay Awake

Researchers used the Maintenance of Wakefulness Test, which measures how long a person can remain awake under quiet conditions that encourage sleep.

From baseline to week 12, average MWT sleep latency increased by 14.3 to 19.8 minutes in the Orzeyful groups, compared with decreases of 0.4 to 0.8 minutes with placebo.

The MWT lasts up to 40 minutes. A latency of at least 20 minutes was defined as normal in these trials, but the group averages do not mean every participant reached that threshold.

Daytime Sleepiness

Participants also completed the Epworth Sleepiness Scale, a questionnaire that measures the likelihood of dozing in common daily situations.

Scores fell by approximately 9.7 to 11.8 points with oveporexton compared with about 1.5 to 1.7 points with placebo.

Cataplexy

Weekly cataplexy frequency also fell substantially.

Median reductions ranged from approximately 79% to 89% with Orzeyful, compared with about 28% to 39% with placebo.

These findings show that Orzeyful affected several major features of NT1 rather than wakefulness alone. However, the trials lasted 12 weeks, so longer-term real-world experience remains much more limited than it is for medications such as modafinil.

Is Orzeyful Better Than Modafinil?

There is currently no good basis for saying that Orzeyful is simply “better” than modafinil.

The pivotal Orzeyful trials compared oveporexton with placebo, not modafinil.

That means the improvements seen in the phase 3 trials cannot be used to calculate whether Orzeyful works better than modafinil.

Modafinil has decades of clinical use behind it, is available generically and is approved for excessive sleepiness associated with narcolepsy without an NT1-specific indication, whereas Orzeyful belongs to a newly approved drug class that directly activates OX2 receptors.

Orzeyful’s phase 3 trials also measured cataplexy alongside wakefulness and sleepiness.

For an individual patient, the more useful question is therefore not necessarily “Which drug is stronger?” but which symptoms are being treated and how the benefits, risks and practical differences compare.

Does Orzeyful Replace Modafinil?

Orzeyful’s approval does not establish that people taking modafinil should automatically switch treatments.

Orzeyful differs from modafinil because its phase 3 trials measured effects on cataplexy as well as wakefulness and daytime sleepiness. How clinicians will position it relative to established narcolepsy treatments, including modafinil, is still being established in practice.

Current AASM narcolepsy guidance predates Orzeyful’s approval, so formal guideline recommendations on where it should sit relative to established treatments are not yet available.

Who Is Orzeyful Approved For?

In the United States, Orzeyful is approved for adults with narcolepsy type 1, also described in the FDA prescribing information as narcolepsy with cataplexy.

It is not currently FDA-approved for:

• narcolepsy type 2
• children or adolescents under 18
• general fatigue
• cognitive enhancement
• people who simply want to stay awake longer

The U.S. label states that safety and effectiveness in pediatric patients have not been established.

Pregnancy data are also limited. Available clinical-trial data are insufficient to determine whether Orzeyful increases the risk of major birth defects, miscarriage or other adverse pregnancy outcomes. A pregnancy exposure registry is available.

There are no data available on the presence of oveporexton in human milk, its effects on the breastfed infant or its effects on milk production.

The label also advises avoiding Orzeyful in people with severe hepatic impairment (Child-Pugh C) and in people with severe renal impairment who are on dialysis, because the drug has not been adequately studied in those populations.

How Are Orzeyful and Modafinil Taken?

Modafinil is generally taken once daily in the morning for narcolepsy.

The FDA-recommended dose is 200 mg once daily.

Orzeyful is taken twice after awakening, using either of the FDA-recommended schedules below:

• 1 mg after awakening followed by another 1 mg three to five hours later, or
• 2 mg after awakening followed by another 2 mg three to five hours later.

The maximum recommended total dose is 4 mg per day.

Orzeyful may be taken with or without food and should be taken at approximately the same times each day.

What Side Effects and Drug Interactions Should Patients Know About?

Orzeyful

The most common adverse reactions in the phase 3 studies were insomnia, increased urinary frequency, urinary urgency and increased salivation. Insomnia occurred in 55% to 60% of Orzeyful-treated patients, compared with 1% receiving placebo, while urinary frequency occurred in 53% to 58%, compared with 5% receiving placebo. The label advises clinicians to discuss the risk of insomnia before treatment, screen for lower urinary tract symptoms and monitor patients with a history of overactive bladder for worsening urinary symptoms.

The FDA label also includes a warning about elevations in creatine phosphokinase, an enzyme that can rise with muscle injury.

Patients are advised to report unexplained muscle pain, weakness or dark urine, particularly if they are exercising vigorously or taking other medications associated with muscle injury.

Orzeyful also has important CYP3A-related drug interactions. Use with strong CYP3A inhibitors is contraindicated. Moderate CYP3A inhibitors require a dose reduction, while strong or moderate CYP3A inducers should generally be avoided because they may reduce drug exposure.

Orzeyful also has potential for abuse and misuse. The FDA label advises clinicians to assess patients for a recent history of drug abuse, particularly CNS stimulant abuse, and to monitor for signs of misuse or abuse. Its federal controlled-substance schedule is still pending DEA review as of October 5, 2026.

Modafinil

Common modafinil side effects include headache, nausea, nervousness, anxiety and insomnia.

The Provigil label also carries warnings for serious skin reactions, angioedema and anaphylaxis, multi-organ hypersensitivity, psychiatric symptoms, persistent sleepiness that may affect driving or other hazardous activities, and cardiovascular events. It is contraindicated in people with known hypersensitivity to modafinil or armodafinil.

Modafinil can affect drug-metabolising enzymes and can reduce the effectiveness of steroidal hormonal contraceptives. The label recommends alternative or additional contraception during treatment and for one month after stopping modafinil.

Modafinil is also a federally controlled substance. It is classified as Schedule IV, and its prescribing information states that it has abuse potential and recommends monitoring for signs of misuse or abuse, particularly in people with a history of drug or stimulant abuse.

Can Orzeyful and Modafinil Be Used Together?

The FDA label does not list modafinil as a contraindication to Orzeyful and does not provide a specific regimen for using the two together. Although modafinil is a weak CYP3A inducer, the Orzeyful label states that no clinically meaningful interaction is expected with weak CYP3A inducers.

Whether the two medications should be used together is an individual treatment decision that should be reviewed with the prescribing sleep specialist and pharmacist rather than managed by adding, stopping or changing either drug independently.

Does Orzeyful Cure Narcolepsy Type 1?

No.

Orzeyful acts on a biological pathway central to NT1, but it does not reverse the loss of orexin-producing neurons. Stimulating the remaining orexin receptors can improve symptoms without reversing the underlying neuronal loss.

Narcolepsy remains a chronic neurological condition, and treatment is aimed at controlling its effects rather than eliminating the disease permanently.

Does Orzeyful Affect Focus and Memory?

Cognitive difficulties are increasingly recognised as part of the burden of NT1.

In a secondary analysis of exploratory cognitive outcomes from an eight-week phase 2 trial, adults with NT1 who received oveporexton showed improvements on several measures of attention, memory and executive function compared with placebo.

Because the participants had NT1, improvements in attention or memory cannot be interpreted as evidence that oveporexton enhances cognition above normal levels in healthy people.

Modafinil has also been studied experimentally in healthy, non-sleep-deprived volunteers and has been reported in the literature as being used nonmedically for cognitive enhancement.

Comparable evidence does not currently establish Orzeyful as a cognitive enhancer in healthy people. Its FDA label also states that Orzeyful has potential for abuse and misuse, so the available evidence does not support using it nonmedically for studying, productivity or staying awake longer.

Where Does Orzeyful Fit Among Other Narcolepsy Treatments?

Narcolepsy treatment was already broader than modafinil before Orzeyful arrived.

Depending on the symptoms involved, established narcolepsy treatments include:

• modafinil
• armodafinil
• solriamfetol
• pitolisant
• sodium oxybate
• dextroamphetamine
• methylphenidate

Some antidepressants have also been used off-label for cataplexy, although the 2021 AASM guideline did not make a recommendation for SSRIs or SNRIs because the evidence was insufficient or inconclusive.

Narcolepsy medications target different symptoms: some primarily improve daytime wakefulness, while others can also address cataplexy or disrupted nighttime sleep.

Unlike treatments aimed primarily at individual symptoms, Orzeyful acts directly on the orexin pathway and demonstrated effects on several major NT1 symptoms in clinical trials.

Can Patients Get Orzeyful Yet?

As of October 5, 2026, Orzeyful is FDA-approved but is not yet commercially available in the United States.

Takeda’s current Orzeyful site says availability is expected by November 2026 and remains pending completion of DEA scheduling.

This status should be re-checked immediately before publication because it is likely to change soon.

What Does This Mean for People With Narcolepsy?

If You Have Recently Been Diagnosed

Because Orzeyful is currently approved only for adults with NT1, knowing whether the diagnosis is NT1 or NT2 affects whether this treatment is within its approved indication.

If You Already Take Modafinil

The approval of Orzeyful does not by itself mean that someone taking modafinil should switch treatment.

People already using modafinil should discuss whether the new option changes their treatment plan with their sleep specialist rather than stopping or switching medication on their own.

If Your Symptoms Are Not Well Controlled

For adults with NT1 whose symptoms remain inadequately controlled, the Orzeyful trials provide new evidence on wakefulness, daytime sleepiness and cataplexy that can be discussed with a sleep specialist alongside existing treatment options.

If You Are Still Trying to Work Out Whether You Have Narcolepsy

Neither modafinil nor Orzeyful should substitute for a diagnosis.

Persistent excessive daytime sleepiness, episodes suggestive of cataplexy, recurrent sleep paralysis or vivid hallucinations around sleep are reasons to seek assessment, particularly when symptoms interfere with driving, school, work or daily activities.

What Should You Ask a Sleep Specialist?

Useful questions may include:

• Do I have narcolepsy type 1 or type 2?
• Which of my symptoms are currently not well controlled?
• Is my current medication mainly treating sleepiness or other symptoms as well?
• Is Orzeyful within its approved indication for me?
• Would it replace an existing medication or potentially be used alongside one?
• Could my current medications interact with Orzeyful?
• What side effects should I watch for?
• How much long-term experience is available with Orzeyful?
• If I am doing well on modafinil, does the new approval change anything about my treatment plan?

What Do We Still Not Know About Orzeyful?

Orzeyful has positive evidence from two 12-week randomized phase 3 trials, but it is still a newly approved medication.

We do not yet have decades of real-world safety experience comparable with modafinil.

We also do not yet know how commonly clinicians will use Orzeyful instead of established wake-promoting treatments, how often it will be combined with other narcolepsy medications, or how its effectiveness and tolerability will compare with established treatments in everyday clinical practice.

Its current U.S. approval is also restricted to adults with NT1. Whether orexin receptor agonists eventually find a role in other sleep disorders or broader patient groups remains an area for future research.

What Does Orzeyful Change?

Modafinil and Orzeyful come from two different eras of narcolepsy treatment.

Modafinil became an important treatment because it gave people with narcolepsy another way to improve daytime wakefulness. At roughly the same time, researchers were only beginning to discover the orexin system and understand how profoundly it is disrupted in NT1.

Nearly three decades later, Orzeyful turns that biological knowledge into a treatment strategy.

It does not make modafinil obsolete. It has not been proven superior to modafinil in a head-to-head trial, and it does not cure narcolepsy.

What it does change is the therapeutic target. For the first time, an FDA-approved medication for NT1 directly stimulates the orexin signalling system at the centre of the disorder.

For adults with NT1, Orzeyful therefore represents a different treatment strategy from conventional wake-promoting therapy: direct activation of the orexin-2 receptor.

References

American Academy of Sleep Medicine. (2021). Treatment of central disorders of hypersomnolence: Clinical practice guideline. https://doi.org/10.5664/jcsm.9328

Battleday, R. M., & Brem, A. K. (2015). Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. European Neuropsychopharmacology, 25(11), 1865–1881. https://doi.org/10.1016/j.euroneuro.2015.07.028

Food and Drug Administration. (2025). Provigil (modafinil) prescribing information. U.S. Department of Health and Human Services.

Food and Drug Administration. (2026). Orzeyful (oveporexton) prescribing information. U.S. Department of Health and Human Services.

Food and Drug Administration. (2026, August 5). FDA approves first drug to treat the full range of narcolepsy type 1 symptoms. U.S. Department of Health and Human Services.

Lammers, G. J., Plazzi, G., Mignot, E., et al. (2026). Effects of oveporexton, an orexin receptor 2-selective agonist, on cognition in narcolepsy type 1: A secondary analysis of a randomized clinical trial. JAMA Neurology, 83(2), 145–152.

Mayo Clinic. (n.d.). Narcolepsy: Diagnosis and treatment.

Mayo Clinic. (n.d.). Narcolepsy: Symptoms and causes.

National Heart, Lung, and Blood Institute. (n.d.). Narcolepsy. National Institutes of Health.

Takeda Pharmaceutical Company Limited. (2026). Orzeyful availability information.

von Hehn, C., Hang, Y., Yao, B., et al. (2026). Oveporexton for narcolepsy type 1: Results from two phase 3 trials. The New England Journal of Medicine, 395, 1166–1179.